Rabeprazole sodium 5 mg + Rabeprazole sodium 10 mg + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroesophageal Reflux
Conditions
Gastroesophageal Reflux
Trial Timeline
Nov 1, 2009 → Nov 1, 2011
NCT ID
NCT00992589About Rabeprazole sodium 5 mg + Rabeprazole sodium 10 mg + Placebo
Rabeprazole sodium 5 mg + Rabeprazole sodium 10 mg + Placebo is a phase 3 stage product being developed by Eisai for Gastroesophageal Reflux. The current trial status is completed. This product is registered under clinical trial identifier NCT00992589. Target conditions include Gastroesophageal Reflux.
What happened to similar drugs?
4 of 20 similar drugs in Gastroesophageal Reflux were approved
Approved (4) Terminated (1) Active (16)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00992589 | Phase 3 | Completed |
Competing Products
20 competing products in Gastroesophageal Reflux